IP Library Granted Patent US 9,351,963
Granted Patent B2
US 9,351,963 · App. 13/911,234 · Granted May 31, 2016

Defensin-like molecules as novel antimicrobial agents

Inventors: Erik De Leeuw (Baltimore, MD); Alexander D. Mackerell, Jr. (Baltimore, MD)
Assignee: University of Maryland, Baltimore
A61K31/428A61K31/05A61K31/09A61K31/35A61K31/351A61K31/40A61K31/403A61K31/404A61K31/4174A61K31/433A61K31/4709
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,351,963
App. No.
13/911,234
Granted
May 31, 2016
Kind
B2
Abstract

Disclosed are compositions and methods for treating and/or preventing infections in mammals, by administering to a mammal a therapeutically effective amount of at least one defensin-like molecule, e.g., in a composition that includes such molecule. Also disclosed are kits that include such molecules, or compositions that include such molecules, as well as instructions for using such molecules to treat a mammal.

Claims (10)

1. A method of treating an infection in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one molecule selected from the group consisting of

Compound D, BAS00127538 (Asinex, 3-PC-2)

and, derivatives, and analogs thereof, wherein said infection is caused by microorganisms comprising one or more gram-positive bacteria selected from the group consisting of Staphylococcus, Streptococcus , and Enterococcus.

2. The method of claim 1 , wherein said gram-positive bacteria comprises one or more bacteria selected from the group consisting of Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group, Enterococcus faecalis, Enterococcus faecium , and Bacillus Anthracis.

3. The method of claim 1 , wherein said infection is sepsis.

4. A method of killing a bacterial population in a mammal comprising administering to a mammal infected with at least one bacterial population a therapeutically effective amount for killing the bacterial population, of at least one molecule selected from the group consisting of:

Compound D, BAS00127538 (Asinex, 3-PC-2)

and, derivatives, and analogs thereof, wherein said infection is caused by microorganisms comprising one or more gram-positive bacteria selected from the group consisting of Staphylococcus, Streptococcus , and Enterococcus.

5. The method of claim 4 , wherein the bacterial population comprises at least one bacteria selected from the group consisting of Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group, Enterococcus faecalis, Enterococcus faecium , and Bacillus Anthracis.

6. The method of claim 4 , wherein the at least one compound is administered to the mammal as part of a composition.

Assignments (3)
CONFIRMATORY LICENSE Recorded Jun 25, 2013
From: THE UNIVERSITY OF MARYLAND, BALTIMORE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 030678/0774 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2013
From: DE LEEUW, ERIK; MACKERELL, ALEXANDER
To: UNIVERSITY OF MARYLAND, BALTIMORE
Reel/Frame 030557/0612 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2013
From: POLI, FRANCESCA
To: LINO MANFROTTO + CO. S.P.A.
Reel/Frame 030557/0716 →
Continuity (3)
Provisional Application 61656039 · Jun 6, 2012
Provisional Application 61410112 · Nov 4, 2010
Related Publication 20130331413A1 · Dec 12, 2013